期刊
STAR PROTOCOLS
卷 3, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.xpro.2021.101079
关键词
-
资金
- European Research Council (ERC) [10218]
- Dutch Cancer Society (KWF)/Alpe d'HuZes Bas Mulder Award [292]
- Foundation Children Cancer Free (KiKa)
- Oncode Institute
- [850571]
Patient-derived and normal tissue-derived tumor organoids are useful for predicting treatment responses and drug toxicity testing. Combining both types of organoids allows for screening of tumor-specific drug vulnerabilities.
Patient-derived tumor organoids can be predictive of patient's treatment re-sponses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor -spe-cific drug vulnerabilities. Here, we provide a detailed protocol for organoid drug screening using, as proof-of-principle, patient-derived malignant rhabdoid tumor organoids. The protocol can be adapted for drug testing on any tumor and/or normal tissue-derived organoid culture. For complete details on the use and execution of this protocol, please refer to Calandrini et al. (2021).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据